(67 days)
The Insulin Pen Needle (Ordinary Type) is intended for use with pen injector devices for the subcutaneous injection of insulin.
The Insulin Pen Needle (Safety Type) is sterile, single-use safety needle intended for use with pen iniector devices for the injection of insulin.
The proposed devices, Insulin Pen Needle (Ordinary Type) and Insulin Pen Needle (Safety Type) are single use device, which is designed for used with a pen injector for the subcutaneous injection of insulin. For the safety type, it is designed with a sharp injury prevention feature to minimize the risk from accidental needles sticks. The proposed device is available in 29G, 30G, 31G, 32G and 33G five different specifications with the needle length available in 4mm, 5mm, 6mm, 10mm and 12mm for Insulin Pen Needle (Ordinary Type) and 4mm, 5mm, and 8mm for Insulin Pen Needle (Safety Type). The product is for single use and provided sterile (Irradiation). The shelf-life of the product is five-years.
The provided text describes the acceptance criteria and study for an Insulin Pen Needle (Ordinary Type, Safety Type), not an AI/algorithm-based device. Therefore, many of the requested points, such as MRMC studies, training set details, or expert ground truth establishment for AI, are not applicable.
However, I can extract the information relevant to the medical device's performance and testing as described in the 510(k) summary.
Here's a breakdown based on the provided document:
Device Type: Insulin Pen Needle (Ordinary Type, Safety Type) - This is a physical medical device, not a software/AI device.
1. A table of acceptance criteria and the reported device performance:
The document refers to adherence to various ISO standards and specific test results, but does not present a single consolidated table of "acceptance criteria" vs. "reported performance" in a quantitative manner for all aspects. Instead, it states that the device "met all design specifications" and "complies with the following standards."
Here's an attempt to extract the closest information, primarily by listing the standards the device claims to conform with for performance characteristics:
| Feature/Test | Acceptance Criteria (as per standards/claims) | Reported Performance |
|---|---|---|
| General Performance: | ||
| Bond between hub and needle tube (Ordinary Type) | Clause 4.4 of ISO 11608-2:2012; Clause 4.12 of ISO 7864:2016 | Complies with standards (Stated implicitly by "met all design specifications") |
| Needle tip configuration (Ordinary Type) | Conform with ISO 7864 standards | Complies with standards |
| Bond between hub and needle tube (Safety Type) | Drawing force ≥ 22N (29G); Drawing force ≥ 11N (30G-33G); Clause 4.4 of ISO 11608-2:2012; Clause 4.12 of ISO 7864:2016 | Complies with standards and specified drawing forces (Stated implicitly by "met all design specifications") |
| Needle tip configuration (Safety Type) | Conform with ISO 7864 standards | Complies with standards |
| Biocompatibility: | ||
| Cytotoxicity | No Cytotoxicity | Met (Stated "No Cytotoxicity") |
| Intracutaneous reactivity / Irritation | No Irritation to Skin | Met (Stated "No Irritation to Skin") |
| Skin Sensitization | No skin sensitization | Met (Stated "No skin sensitization") |
| Acute Systemic Toxicity | No Systemic Toxicity | Met (Stated "No Systemic Toxicity") |
| Pyrogen | No pyrogen | Met (Stated "No pyrogen") |
| Hemolysis | No hemolysis | Met (Stated "No hemolysis") |
| Subacute Systemic Toxicity | No Subacute Systemic Toxicity | Met (Stated "No Subacute Systemic Toxicity") |
| Sterility: | ||
| Sterility Assurance Level (SAL) | 10⁻⁶ | Achieved 10⁻⁶ |
| Endotoxin Limit | 20 EU per device | Met (Stated "20 EU per device") |
| Shelf-life: | ||
| Shelf life | 5 years | Validated for 5 years |
| Sharps Injury Protection (Safety Type): | ||
| Sharps injury prevention feature | Meet pre-established criteria per ISO 23908:2011 and FDA Guidance | Met pre-established criteria (Tested in simulated clinical use) |
| General Quality: | ||
| Particulate matter | USP <788> acceptance criteria | Met USP acceptance criteria |
| Package integrity | Acceptable for protection and sterility maintenance | All packaging deemed acceptable |
2. Sample size used for the test set and the data provenance:
- Simulated Clinical Use Study (Safety Type only): 600 device samples.
- Data Provenance: Not specified in terms of country of origin for testing data. The manufacturer is in Tianjin, China. The testing appears to be non-clinical, laboratory-based performance testing rather than human clinical study data. It is a non-clinical study, not a retrospective or prospective human data study.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:
- Not Applicable. This is a physical medical device. "Ground truth" in the context of AI/machine learning data is not relevant here. Performance is assessed against engineering standards (e.g., ISO, USP) and physical properties.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set:
- Not Applicable. As this is not a study requiring human interpretation or labeling of data (like medical imaging), there's no adjudication method in the described testing.
5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:
- Not Applicable. This is not an AI/software device. No human-in-the-loop studies or MRMC studies were conducted.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:
- Not Applicable. This is not an AI/software device. "Standalone performance" in this context would refer to the device's adherence to its design specifications and relevant standards, which was evaluated through non-clinical testing.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.):
- Not Applicable. For a physical device, "ground truth" is defined by established engineering and biological standards (e.g., ISO, USP), material specifications, and physical measurements. The "truth" is whether the device physically meets these specifications and passes the required tests.
8. The sample size for the training set:
- Not Applicable. There is no "training set" as this is not an AI/machine learning model.
9. How the ground truth for the training set was established:
- Not Applicable. There is no "training set." The performance of the device is assessed against pre-defined engineering standards and test methods.
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the FDA logo is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
Tianjin Huahong Technology Co., Ltd. Yuan Ying Quality Manager A01, Plant B, No. 278, Hangkong Road, Tianjin Pilot Free Trade Zone(Air Port Industrial Park) Tianiin. 300308 China
Re: K221176
Trade/Device Name: Insulin Pen Needle (Ordinary Type, Safety Type) Regulation Number: 21 CFR 880.5570 Regulation Name: Hypodermic Single Lumen Needle Regulatory Class: Class II Product Code: FMI Dated: June 16, 2022 Received: June 16, 2022
Dear Yuan Ying:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part
{1}------------------------------------------------
801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
For CAPT Alan M. Stevens Assistant Director DHT3C: Division of Drug Delivery and General Hospital Devices. and Human Factors OHT3: Office of GastroRenal, ObGyn, General Hospital and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications for Use
Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2023 See PRA Statement below.
Submission Number (if known)
Device Name
Insulin Pen Needle (Ordinary Type, Safety Type)
Indications for Use (Describe)
The Insulin Pen Needle (Ordinary Type) is intended for use with pen injector devices for the subcutaneous injection of insulin.
The Insulin Pen Needle (Safety Type) is sterile, single-use safety needle intended for use with pen iniector devices for the injection of insulin.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
[X] Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
510(k) Summary - K221176
l Submitter
Tianjin Huahong Technology Co., Ltd.
A01, Plant B, No.278, Hangkong Road, Tianjin Pilot Free Trade Zone (Air Port Industrial Park), 300308 Tianjin, China
Establishment Registration Number: 3009498536
Contact person: Ms. Ying Yuan Quality Manager Tel.: +86-18622179097 E-mail: ying.yuan@hh-technology.com
Preparation date: July 1, 2022
II Proposed Device
| Trade Name of Device: | Insulin Pen Needle (Ordinary Type, Safety Type) |
|---|---|
| Classification name: | Hypodermic, Single Lumen |
| Regulation Number: | 21 CFR 880.5570 |
| Regulatory Class: | Class II |
| Product code: | FMI |
| Review Panel | General Hospital |
III Predicate Devices
| 510(k) Number: | K181069 |
|---|---|
| Trade name: | Disposable Insulin Pen Needle |
| Classification: | Class II |
| Product Code: | FMI |
| Manufacturer | Zhejiang Kindly Medical Devices Co. Ltd |
| 510(k) Number: | K170988 |
| Trade name: | DropSafe Safety Pen Needle |
| Classification: | Class II |
| Product Code: | FMI |
| Manufacturer | HTL-Strefa S.A. |
{4}------------------------------------------------
IV Device description
The proposed devices, Insulin Pen Needle (Ordinary Type) and Insulin Pen Needle (Safety Type) are single use device, which is designed for used with a pen injector for the subcutaneous injection of insulin. For the safety type, it is designed with a sharp injury prevention feature to minimize the risk from accidental needles sticks. The proposed device is available in 29G, 30G, 31G, 32G and 33G five different specifications with the needle length available in 4mm, 5mm, 6mm, 10mm and 12mm for Insulin Pen Needle (Ordinary Type) and 4mm, 5mm, and 8mm for Insulin Pen Needle (Safety Type). The product is for single use and provided sterile (Irradiation). The shelf-life of the product is five-years.
V Indication for use
The Insulin Pen Needle (Ordinary Type) is intended for use with pen injector devices for the subcutaneous injection of insulin.
The Insulin Pen Needle (Safety Type) is sterile, single-use safety needle intended for use with pen injector devices for the injection of insulin.
| Table 1 General Comparison for Insulin Pen Needle (Ordinary Type) | ||
|---|---|---|
| ITEM | Proposed DeviceK202319 | Predicate Device 1K181069 |
| Proprietary/ trade name | Insulin Pen Needle (Ordinary Type) | Disposable Insulin Pen Needle |
| Regulation No. | 880.5570 | 880.5570 |
| Product Code | FMI | FMI |
| Class | II | II |
| Intended Use | The Insulin Pen Needle (Ordinary Type) is intended for use with pen injector devices for the subcutaneous injection of insulin. | The Disposable Insulin Pen Needle is intended for use with pen injector devices for the subcutaneous injection of insulin. |
| Environment of use | In hospital or in the home environment. | In hospital or in the home environment. |
| Type-of-use | Disposable | Disposable |
| Configuration and materials of construction for all components | Needle Tube Stainless Steel | Needle Tube Stainless Steel |
| Needle Hub Polypropylene | Hub Polypropylene | |
| Outer Sheath Polypropylene | Cup Polyethylene | |
| Inner Sheath Polypropylene | Inner Sheath Polypropylene | |
| Sealed PaperPaper | Sealed PaperPaper |
VI Comparison of technological characteristics with the predicate devices
{5}------------------------------------------------
| Operation Mode | For Manual Use Only | For Manual Use Only |
|---|---|---|
| Methodofattachment to peninjector | Through threaded connection | Through threaded connection |
| Table 2 Safety and Performance Comparison for Insulin Pen Needle (Ordinary Type) |
|---|
| Proposed Device | Predicate | |
|---|---|---|
| ITEM | K202319 | Device 1K181069 |
| Needle Gauge | 29G, 30G, 31G, 32G, 33G | 28G, 29G, 30G,31G, 32G, 33G |
| Needle Length | 4mm, 5mm, 6mm, 8mm, 10mm, 12mm | 4mm, 6mm,8mm, 12mm |
| Patient-contact materials | ||
| Needle Tube | Stainless Steel (SUS304) | Stainless Steel |
| Lubricant | MDX4-4159 | Unknown |
| adhesive | UV glue | Unknown |
| Bond between hub andneedle tube | Clause 4.4 of ISO 11608-2:2012;Clause 4.12 of ISO 7864:2016 | Clause 4.4 of ISO 11608-2:2012;Clause 4.12 of ISO 7864:2016 |
| Design specification of theinner sheath (dimensions,color, materials andstrength) | 14.35.85.8mm;Transparent color; Polypropylene;Tensile stress at yield>20MPa; Flexuralmodulus: >800MPa; Charpy NotchedImpact Strength (23°C ) >2.8kJ/m². | Unknown |
| Design specification of theouter sheath (dimensions,color, materials andstrength) | 30.313.413.4mm;Transparent color; Polypropylene;Tensile stress at yield>20MPa; Flexuralmodulus: >800MPa; Charpy NotchedImpact Strength (23°C ) >2.8kJ/m². | Unknown |
| Needle tip configuration | Conform with ISO 7864 standards | Conform withISO 7864standards |
| Cytotoxicity | No Cytoxicity | No Cytoxicity |
| Intracutaneous reactivity | No Irritation to Skin | No Irritation to Skin |
| Skin Sensitization | No skin sensitization | No skin sensitization |
| Acute Systemic Toxicity | No Systemic Toxicity | No Systemic Toxicity |
| Pyrogen | No pyrogen | No pyrogen |
{6}------------------------------------------------
| Hemolysis | No hemolysis | |
|---|---|---|
| Subacute Systemic Toxicity | No Subacute Systemic Toxicity | Unknown |
| Method | Irradiation Sterilized | EO Sterilized |
| SAL | 10-6 | 10-6 |
| Endotoxin Limit | 20 EU per device | 20 EU per device |
| Shelf life | 5 years | Unknown |
| Label/ Labeling | Complied with 21 CFR part 801 | Complied with 21 CFR part 801 |
Table 3 General Comparison for Insulin Pen Needle (Safety Type)
| ITEM | Proposed Device | Predicate Device 2 |
|---|---|---|
| K202319 | K170988 | |
| Regulation No. | 880.5570 | 880.5570 |
| Product Code | FMI | FMI |
| Class | II | II |
| Intended Use | The Insulin Pen Needle (Safety Type) is sterile, single-use safety needle intended for use with pen injector devices for the injection of insulin. | The DropSafe Safety Pen Needles are sterile, single-use safety needles intended for use with pen injector devices for the injection of drugs. |
| Environment of use | In hospital or in the home environment. | In hospital or in the home environment. |
| Proprietary/ trade name | Insulin Pen Needle (Safety Type) | DropSafe Safety Pen Needles |
| Type-of-use | Disposable | Disposable |
| Configuration and materials of construction for all components | Needle Tube Stainless Steel (SUS304) | Cannula Medical grade stainless steel |
| Needle Hub Polypropylene | Hub Plastic resin | |
| Outer Sheath Polypropylene | Primary container Plastic resin | |
| Inner Sheath Polypropylene | Slider Unknown | |
| Sealed Paper Paper | Seal Unknown | |
| Spring Stainless Steel (SUS304) | Spring- operated Stainless steel wire | |
| Upper Cover Polypropylene | Needle shield Plastic resin |
{7}------------------------------------------------
| Operation Mode | For Manual Use Only | For Manual Use Only | |
|---|---|---|---|
| Method ofattachment to peninjector | Threaded connection method. | Threaded connection method. | |
| Safety Feature | Prevent from needlestick | Prevent from needlestick | |
| Method ofactivation | Trigger shield | Trigger shield |
| ITEM | Proposed DeviceK202319 | Predicate Device 2K170988 |
|---|---|---|
| Needle Gauge | 29G, 30G, 31G, 32G, 33G | 31G |
| Needle Length | 4mm, 5mm, 6mm, 8mm | 6mm and 8mm |
| Patient-contact material | ||
| Needle Tube | Stainless Steel (SUS304) | Medical grade stainless steel |
| Lubricant | MDX4-4159 | Unknown |
| adhesive | UV glue | Unknown |
| Bond between hub andneedle tube | Drawing force≥22N (29G) ;Drawing force≥ 11N (30G-33G);Clause 4.4 of ISO11608-2:2012;Clause 4.12 of ISO 7864:2016 | Clause 4.4 of ISO 11608-2:2012;Clause 4.12 of ISO 7864:2016 |
| Design specification of theinner sheath (dimensions,color, materials andstrength) | 21.510.79.8mm;Transparent color;Polypropylene.Tensile stress atyield>20MPa; Flexuralmodulus: >800MPa;Charpy Notched ImpactStrength (23°C ) >2.8kJ/m² . | Unknown |
| Design specification of theouter sheath (dimensions,color, materials andstrength) | 43.818.618.6mm;Transparent color;Polypropylene.Tensile stress atyield>20MPa; Flexuralmodulus: >800MPa;Charpy Notched ImpactStrength (23°C ) >2.8kJ/m². | Unknown |
| Design specification of theupper cover (dimensions, | 30.214.614.6mm;White: | Unknown |
| color, materials andstrength) | Polypropylene.Tensile stress atyield>20MPa; Flexuralmodulus: >800MPa;Charpy Notched ImpactStrength (23°C) >2.8kJ/m². | |
| Needle tip configuration | Conform with ISO 7864 standards | Conform with ISO 7864 standards |
| Biocompatibility | ||
| Cytotoxicity | No Cytoxicity | |
| Intracutaneous reactivity | No Irritation to Skin | |
| Skin Sensitization | No skin sensitization | Conform with ISO 10993 standards |
| Acute Systemic Toxicity | No Systemic Toxicity | |
| Pyrogen | No pyrogen | |
| Hemolysis | No hemolysis | |
| Subacute Systemic Toxicity | No Subacute SystemicToxicity | Unknown |
| Sterilization | ||
| Method | Irradiation Sterilized | Irradiation Sterilized |
| SAL | 10-6 | 10-6 |
| Endotoxin Limit | 20 EU per device | 20 EU per device |
| Shelf life | 5 years | Unknown |
| Label/ Labeling | Complied with 21 CFR part 801 | Complied with 21 CFR part 801 |
Table 4 Safety and Performance Comparison for Insulin Pen Needle (Safety Type)
{8}------------------------------------------------
VII Compatible injectors
The Insulin Pen Needle can be used in combination with following pen injector available and cleared in the USA:
- Autopen ® K983974 Owen Mumford, Inc.
- Novopen Echo ® K162602 Novo Nordisk Inc.
- Humapen and Humapen Ergo K982842 Eli Lilly and Company -
- Humapen Luxura K142518 Eli Lilly and Company -
- -Humapen Memoir K053563 Eli Lilly and Company
VIII Non-Clinical Testing
Non clinical tests were conducted to verify that the proposed device met all design specifications and that the subject device is Substantially Equivalent (SE) to the predicate device. The test results demonstrated that the proposed device complies with the following standards:
Performance Testing:
{9}------------------------------------------------
-
ISO 7864: 2016 Sterile hypodemic needles for single use
-
ISO 9626: 2016 Stainless steel needle tubing for the manufacture of medical devices
-
ISO 11608-2: 2012 Needle-based injection systems for medical use- Requirements and test methods- Part 2: Needles
- ハ ISO 23908 :2011 Sharps injury protection - Requirements and test methods -Sharps protection features for single-use hypodermic needles, introducers for catheters and needles used for blood sampling
Biocompatibility Testing:
In accordance with ISO 10993-1, the Insulin Pen Needles are classified as: Externally communicating, indirect blood path with prolonged contact duration (>24 h to 30 d). The direct and indirect patient-contact component(s) along with the material(s) for the proposed devices are identified as follows:
| Components | Material | Contact Level | Contact Duration |
|---|---|---|---|
| Needle Tube | Stainless Steel(SUS304) | Indirect, blood path | prolonged (>24hrs to 30 days) |
| Adhesive | UV glue | Indirect, blood path | prolonged (>24hrs to 30 days) |
| Lubricant | MDX4-4159 | Indirect, blood path | prolonged (>24hrs to 30 days) |
| Needle hub | Polypropylene | Direct contact with intact skin | Limited (≤24 h) |
| Outer sheath | Polypropylene | Direct contact with intact skin | Limited (≤24 h) |
Table 5 Patient Contact Material Identification
The following testing was conducted:
- . Cytotoxicity
- . Sensitization
- Irritation ●
- . Acute Systemic Toxicity
- Material-Mediated Pyrogenicity .
- Subacute Toxicity .
- . Hemocompatibility
Particulate matter testing was conducted in accordance with USP <788> Particulate Matter in Injections and met the USP acceptance criteria.
Sterility, Shipping and Shelf-Life
The Insulin Pen Needles were sterilized by irradiation to achieve a SAL of 10 °. The radiation source
{10}------------------------------------------------
was Electron beam, and the radiation dose was 25kGy, which was established according to VDmax method per ISO11137-2, Sterilization of healthcare products-Radiation establishing the sterilization dose. The sterilization was validated according to ISO 11137-2. The Insulin Pen Needles were evaluated for bacterial endotoxin utilizing the USP <85> Limulus Amebocyte Lysate (LAL) method.
- . Package integrity testing, after environmental conditioning and simulated transportation was conducted on the final, packaged, and sterile devices. All packaging deemed acceptable for protection of product and sterility maintenance.
- Sterile Barrier Packaging Testing performed on the proposed device: .
- Seal strength ASTM F88/F88-15 o
- o Dye penetration ASTM F1929-15
Shelf life of 5 years is validated using the FDA recognized standard ASTM F1980-16 Standard Guide for Accelerated Aging of Sterile Barrier Systems for Medical Devices
Simulated Clinical Use
A simulated clinical use study was performed on 600 device samples for the Insulin Pen Needle (Safety Type) according to FDA Guidance (Guidance for Industry and FDA Staff: Medical Device with Sharps Injury Prevention Feature) and ISO 23908:2011 to evaluate the safety mechanism of the proposed device. The results demonstrated that the proposed device met the pre-established criteria.
VIII Clinical Testing
No clinical study is included in this submission.
IX Conclusion
The clinical and non-clinical performance testing demonstrate that the subject device is as safe and effective as the predicate. Therefore, the subject device is substantially equivalent to the predicate device.
§ 880.5570 Hypodermic single lumen needle.
(a)
Identification. A hypodermic single lumen needle is a device intended to inject fluids into, or withdraw fluids from, parts of the body below the surface of the skin. The device consists of a metal tube that is sharpened at one end and at the other end joined to a female connector (hub) designed to mate with a male connector (nozzle) of a piston syringe or an intravascular administration set.(b)
Classification. Class II (performance standards).